EY: 65% of Healthcare Organizations Have Seen a Positive Return on Health Equity Efforts
A new report from Ernst & Young revealed that healthcare organizations are seeing financial benefits and improved outcomes from their health equity strategies.
A new report from Ernst & Young revealed that healthcare organizations are seeing financial benefits and improved outcomes from their health equity strategies.
The industry faces challenges from inflation to labor shortages, according to an annual report from EY. However, there are grounds for optimism and areas to focus on, such as patching up supply chains.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
An EY survey of 347 physicians and healthcare executives found respondents have undertaken staff satisfaction-related projects and are planning initiatives around analytics.
Hospitals and health systems face multiple challenges as they transition away from fee-for-service models and toward value-based care. A new survey from EY dug deeper into this issue.
Despite reimbursement, regulatory, and political uncertainty, the global biotech industry held steady in 2016, according to a new report by professional services firm EY (formerly Ernst & Young).
Plus, coverage of BIO 2016, progress on health IT interoperability and a fundraise for a concierge care startup.
As Ernst & Young noted on several occasions, the biotech sector has matured and must now face adult problems.
The lack of innovation in the medical device industry can be attributed to the lessening dollars being funneled into startups, a new report from Ernst & Young says.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The medical device industry, long the backbone of Minnesota's high tech economy, faces perhaps its most challenging environment in decades. From regulatory headaches and health care reform to a dearth of venture capital, medical device stakeholders face a swirling mix of uncertainty and anxiety.